Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard R P Warner

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Pancreas|October 7, 2011
Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumorsThomas Curran, Sheryl Tulin-Silver, Kalpesh Patel, et al.
Pancreas|October 17, 2015
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver MetastasesMichelle Kang Kim, Fei Ye, Daguang Wang, et al.
Pancreas|July 29, 2010
The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectumLowell B Anthony, Jonathan R Strosberg, David S Klimstra, et al.
Annals of Surgical Oncology|January 9, 2009
In vitro chemoresistance testing in well-differentiated carcinoid tumorsJohn M Lyons, Jeffrey Abergel, Jessica L Thomson, et al.
American Journal of Clinical Oncology|June 6, 2008
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patientsAndrew S Kennedy, William A Dezarn, Patrick McNeillie, et al.
Journal of Gastrointestinal Cancer|March 9, 2020
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid SyndromeJoseph S Dillon, Matthew H Kulke, Dieter Hörsch, et al.
The Oncologist|January 18, 2019
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid SyndromeLowell B Anthony, Matthew H Kulke, Martyn E Caplin, et al.
Endocrine-Related Cancer|January 14, 2018
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trialMarianne Pavel, David J Gross, Marta Benavent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid SyndromeMatthew H Kulke, Dieter Hörsch, Martyn E Caplin, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Pancreas|October 7, 2011
Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumorsThomas Curran, Sheryl Tulin-Silver, Kalpesh Patel, et al.
Pancreas|October 17, 2015
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver MetastasesMichelle Kang Kim, Fei Ye, Daguang Wang, et al.
Pancreas|July 29, 2010
The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectumLowell B Anthony, Jonathan R Strosberg, David S Klimstra, et al.
Annals of Surgical Oncology|January 9, 2009
In vitro chemoresistance testing in well-differentiated carcinoid tumorsJohn M Lyons, Jeffrey Abergel, Jessica L Thomson, et al.
American Journal of Clinical Oncology|June 6, 2008
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patientsAndrew S Kennedy, William A Dezarn, Patrick McNeillie, et al.
Journal of Gastrointestinal Cancer|March 9, 2020
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid SyndromeJoseph S Dillon, Matthew H Kulke, Dieter Hörsch, et al.
The Oncologist|January 18, 2019
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid SyndromeLowell B Anthony, Matthew H Kulke, Martyn E Caplin, et al.
Endocrine-Related Cancer|January 14, 2018
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trialMarianne Pavel, David J Gross, Marta Benavent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid SyndromeMatthew H Kulke, Dieter Hörsch, Martyn E Caplin, et al.
Pageof 4